Program
(Program subject to change)

Program Sunday, 9 September 2018

8:00 AM - 12:00 PM
SHORT COURSE MORNING SESSION
(Short course registration required) See Full Short Course Program
12:30 PM - 7:30 PM
RESEARCH POSTER PRESENTATIONS - SESSION I
1:00 PM - 1:30 PM
WELCOME
1:30 PM - 1:45 PM
OPENING SPEECH
1:45 PM - 3:15 PM
FIRST PLENARY SESSION
Transforming Healthcare and Leveraging Digital Health for Better Health in Asia-Pacific
Digital disruption impacts every industry, and healthcare is no exception. Digital technologies are transforming the global healthcare landscape and driving healthcare towards better value through improving efficiency and quality and reducing costs. The Asia-Pacific region has a highly fragmented healthcare market and its digital transformation is coming into its own. Approaches to digital health in different countries across the region differ widely. The opening plenary will explore how to fully grasp the benefits and potential of digital health: What is the current reality and future of digital health in the region? What are the drivers and barriers for the uptake and deployment of digital health? How can we take digital health to the next level?
3:15 PM - 3:45 PM
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I
3:45 PM - 4:45 PM
BREAKOUT SESSION

3:45 PM - 4:45 PM

IP1: COST VS VALUE: WHAT IS THE FAIR PRICE OF A DRUG?

Moderator:

Neal Somchand, MSc., Principal, Deallus Consulting, Tokyo, Japan

Panelists:

Mark Sculpher, PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK

Takashi Fukuda, PhD, Director, National Institute of Public Health, Wako, Japan

Christoph Glaetzer, Dipl. Kfm, VP Global Market Access I Health Economics I Pricing I PRO I RWE, Janssen, Pharmaceutical Companies of Johnson&Johnson, NJ, NJ, USA


3:45 PM - 4:45 PM

IP2: OPPORTUNITIES AND CHALLENGES IN INTERNATIONAL HARMONIZATION OF HTA OF MEDICAL DEVICES – GAPS BETWEEN EUROPEAN AND ASIAN COUNTRIES

Moderator:

Rosanna Tarricone, MSc, PhD, Associate SDA Dean, SDA Bocconi School of Management, Bocconi University, Milano, Italy

Panelists:

Ataru Igarashi, PhD, Associate Professor, The University of Tokyo, Tokyo, Japan

Sukyeong Kim, PhD, RPh, MPH, Senior Research Fellow, National Evidence-Based Healthcare Collaborating Agency (NECA), Seoul, Korea, Republic of (South)


3:45 PM - 4:45 PM
W1: HEALTH ECONOMIC EVALUATIONS TO SUPPORT PUBLIC HEALTH DECISION-MAKING IN VACCINES: ARE COST-EFFECTIVENESS ANALYSIS AND BUDGET IMPACT ANALYSIS SUFFICIENT TO ANSWER THE POLICY QUESTIONS?
Discussion Leaders:

Shunya Ikeda, MD, Professor of Public Health, International University of Health and Welfare, Narita city, Japan

Nathorn Chaiyakunapruk, Pharm.D., Ph.D., Professor of Health Economics, Center of Pharmaceutical Outcomes Research (CPOR), Department of Pharmacy Practice, Naresuan University, Phitsanulok, Thailand

Baudouin Standaert, MD, PhD, Senior Director, Lead of Health Economics, GSK Vaccines, Wavre, Belgium

Sharon Zhang, Ph D, Director of Epidemiology and Health Economics, Region International, GSK Vaccines, Singapore, Singapore


3:45 PM - 4:45 PM
W2: “BOLT-ONS” FOR UTILITY INSTRUMENTS: WHAT ARE THEY AND HOW SHOULD THEY BE DEVELOPED AND USED?
Discussion Leaders:

Kim Rand, PhD, Researcher, Department of Health Management and Health Economics, University of Oslo, Oslo, Norway

Mark Oppe, PhD, Senior Scientist, EuroQol Research Foundation, Rotterdam, The Netherlands

Nan Luo, Ph.D., Associate Professor, Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore

Jan van Busschbach, Professor, Psychiatry, section MPP, Erasmus University Medical Center, Rotterdam, The Netherlands


3:45 PM - 4:45 PM
P1: COST STUDIES

CS1

3:45 PM - 4:00 PM

FACTORS IMPACTING DIRECT COSTS OF CHRONIC KIDNEY DISEASE AMONG CHINESE URBAN PATIENTS IN PRE-DIALYSIS PHASE

Liu Y1, Wang J2, Yang L2
1University of Missouri - Kansas City, Kansas City, MO, USA, 2Peking University, Beijing, China

CS2

4:00 PM - 4:15 PM

ESTIMATION OF LIFE EXPECTANCY, EXPECTED YEARS OF LIFE LOST, AND LIFETIME COST DUE TO INTRACEREBRAL HAEMORRHAGE IN KOREA

Cheon S1, Lee H2, Jang B2, Wang J1
1National Cheng Kung University, Tainan, Taiwan, 2Kyung Hee University, Seoul, Korea, Republic of (South)

CS3

4:15 PM - 4:30 PM

DIRECT MEDICAL COSTS ASSOCIATED WITH CARDIOVASCULAR DISEASES AMONG THE HIV-INFECTED PATIENTS IN TAIWAN: A POPULATION-BASED STUDY

Liao C1, Yang C2, Chen P2, Ou H2, Toh HS1, Chen Z3, Ko N2
1Chimei Medical Center, Tainan City, Taiwan, 2National Cheng Kung University, Tainan City, Taiwan, 3Chimei Medical Center, Tainan, Taiwan

CS4

4:30 PM - 4:45 PM

HEALTHCARE RESOURCE UTILIZATION AND ECONOMIC BURDEN OF HERPES ZOSTER IN JAPANESE PATIENTS WITH IMMUNOCOMPROMISED CONDITIONS: A CLAIMS DATABASE COHORT STUDY

Imafuku S1, Mizukami A2, Goto Y3, Ito C4, Curran D5, Holl K2, Matsuki T2
1Fukuoka University School of Medicine, Fukuoka, Japan, 2GSK, Tokyo, Japan, 3National Cancer Center Hospital, Tokyo, Japan, 4Japan Medical Data Center Co., Ltd., Tokyo, Japan, 5GSK, Wavre, Belgium

3:45 PM - 4:45 PM
P2: CARDIOVASCULAR AND DIABETES STUDIES

CV1

3:45 PM - 4:00 PM

TRENDS IN MEDICATION UTILIZATION, GLYCEMIC CONTROL, RATES OF SEVERE HYPOGLYCEMIA AND LOWER LIMB AMPUTATIONS AMONG TYPE 2 DIABETES PATIENTS WITH CHRONIC KIDNEY DISEASE IN SINGAPORE FROM 2012 TO 2017

Cheen MH, Tan YZ, Lim PS, Khee GY, Thumboo J, Goh S, Bee YM
Singapore General Hospital, Singapore, Singapore

CV2

4:00 PM - 4:15 PM

IDENTIFICATION OF LOW RISK STABLE CARDIOVASCULAR PATIENTS AND PATIENT ACCEPTANCE FOR FAST-TRACK MEDICATION REFILL (FTMR) SERVICE

Lee VW1, Kwan WH1, Ko XC1, Yan BP2
1The Chinese University of Hong Kong, Shatin, Hong Kong, 2The Chinese University of Hong Kong, Hong Kong, Hong Kong

CV3

4:15 PM - 4:30 PM

THE PREVALENCE AND BURDEN OF HYPERTENSION AND OBESITY AMONG PATIENTS WITH TYPE 2 DIABETES IN JAPAN

Carpinella CM1, Sternbach N2, Doane MJ3, Fukuda T4, Chen Y5, Stankus AP6
1Kantar Health, San Mateo, CA, USA, 2Kantar Health, New York City, NY, USA, 3Kantar Health, Horsham, PA, USA, 4National Institute of Public Health, Wako, Japan, 5Kantar Health, Singapore, Singapore, 6Kantar Health, New York, NY, USA

CV4

4:30 PM - 4:45 PM

COST-EFFECTIVENESS ANALYSIS OF ACUTE ISCHEMIC STROKE TREATMENT ACCORDING TO COMORBIDITY INDEX

Han E
Yonsei University, Incheon, Korea, Republic of (South)
4:45 PM - 5:00 PM
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I
5:00 PM - 6:00 PM
BREAKOUT SESSION

5:00 PM - 6:00 PM

IP3: HOW WILL PATIENT CENTRICITY BE CAPTURED IN THE JAPANESE HTA AND HEATHCARE REFORM?

Moderator:

Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, UK

Panelists:

Shunya Ikeda, MD, Professor of Public Health, International University of Health and Welfare, Narita city, Japan

Makoto Kobayashi, PhD, MEng, Director and COO, CRECON Medical Assessment Inc., Tokyo, Japan

Durhane Wong-Rieger, BA MA PHD, PRESIDENT & CEO, Canadian Organization for Rare Disorders, Toronto, ON, Canada


5:00 PM - 6:00 PM

IP4: GLOBAL ALIGNMENT ON APPROACHES TO USE OF REAL WORLD EVIDENCE IN DECISION MAKING

Moderator:

Rob Thwaites, MA, MCom, Senior Director, Takeda, London, UK

Panelists:

Nicholas Crabb, PhD, Programme Director, Scientific Affairs, NICE, Manchester, UK

Shunichi Fukuhara, MD, PhD, Professor, Kyoto University, Kyoto, Japan

David Pearce, BPharm, MSc, Senior Director, Pricing Market Access and Health Economics, Pricing Market Access and Health Economics, Takeda Pharmaceuticals, Singapore, Singapore


5:00 PM - 6:00 PM

IP5: BETTER THE DEVIL YOU KNOW? QALYs AND THEIR ALTERNATIVES IN DRUG REIMBURSEMENT DECISION-MAKING

Moderator:

Hansoo Kim, MSc, President of ISPOR-AC, Monash University, Melbourne, Australia

Panelists:

Mark Sculpher, PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK

J. Jaime Caro, MDCM, Chief Scientist, Evidera, Waltham, MA and Adjunct Professor, Medicine, Epidemiology, and Biostatistics, McGill University, Montreal, QC, Canada

Danny Liew, MBBS (Hons), BMedSc, FRACP, PhD, CertHealthEcon, Professor, Monash University, Melbourne, Australia


5:00 PM - 6:00 PM
W3: GENERATING AND COMMUNICATING HEOR EVIDENCE TO DEMONSTRATE PHARMACEUTICAL PRODUCTS’ VALUE: RECOMMENDATIONS FOR CHINESE PAYERS ON EVIDENCE SUBMISSION GUIDELINES
Discussion Leaders:

Xin (Cindy) Gao, PhD, Principal and Asia-Pacific Regional Lead, Pharmerit International, Bethesda, MD, USA

Rong Shao, Ph.D., Professor, Social and Administrative Pharmacy, China Pharmaceutical University, Nanjing, China

Shanlian Hu, MD, MSc, Senior Consultant, Shanghai Health Development Research Center, Shanghai, China


5:00 PM - 6:00 PM
P3: HEALTH TECHNOLOGY ASSESSMENT STUDIES

HT1

5:00 PM - 5:15 PM

INTERNATIONAL COMPARISON OF HTA DECISIONS FOR ONCOLOGY PRODUCTS

Dabbous M1, Achour L2, Chachoua L3, Hanna E4, Toumi M1
1Aix Marseille University, Marseille, France, 2Paris Dauphine University, paris, France, 3Market access society, paris, France, 4Creativ-Ceutical, Paris, France

HT2

5:15 PM - 5:30 PM

THE INTRODUCTION OF HEALTH TECHNOLOGY ASSESSMENT IN JAPAN; LESSONS LEARNED FROM THREE OTHER NEW HTA MARKETS (BRAZIL, POLAND AND SOUTH KOREA)

Escafit M1, Foy C1, Paglia R2
1Consulting at McCann Health, London, UK, 2Consulting at McCann Health, New York, NY, USA

HT3

5:30 PM - 5:45 PM

AN EXPLORATION OF PHARMACOECONOMIC PUBLICATION TRENDS IN JAPAN, SINGAPORE AND CHINA BETWEEN 2000–2018

Wickstead RM1, Tomlinson P1, van Hest N1, Steeves S2, Miah F1, Painter C1, Uchea C1
1Costello Medical, London, UK, 2Costello Medical, Cambridge, UK

HT4

5:45 PM - 6:00 PM

CLINICAL EFFECTIVENESS AND COST-EFFECTIVENESS OF SUGAMMADEX FOR REVERSAL OF NEUROMUSCULAR BLOCK: A RAPID HEALTH TECHNOLOGY ASSESSMENT

Men P1, Gu X1, Zhang H2, Zhai S1
1Department of Pharmacy, Peking University Third Hospital, Beijing, China, 2MSD China Holding Co.Ltd., Shanghai, China

5:00 PM - 6:00 PM
P4: PRICING STUDIES

PR1

5:00 PM - 5:15 PM

VALUE-BASED PRICING IN SINGAPORE: IS IT A RACE TO THE BOTTOM?

Ghosh W, Bose R, Viswambaram A, Brooks-Rooney C
Costello Medical Singapore Pte Ltd, Singapore, Singapore

PR2

5:15 PM - 5:30 PM

THE IMPACT OF GENERIC DRUG ENTRY ON MARKET SHARES AND PRICES OF BRAND-NAME DRUGS– EVIDENCE FROM CHINESE PHARMACEUTICAL MARKET

Chen J, Tian Y, Shi LW
School of Pharmaceutical Sciences, Peking University, Beijing, China

PR3

5:30 PM - 5:45 PM

DRIVERS OF HIGH DRUG PRICES IN JAPAN, A PRELIMINARY RESEARCH

Ueyama M1, Fukushima A2, Oku Y3, Dorey J2, Onishi Y4, François C2, Toumi M5
1Creativ-Ceutical K.K., Tokyo, Japan, 2Creativ-Ceutical, Paris, France, 3Kyoto University, Kyoto, Japan, 4Creativ-Ceutical, Tokyo, Japan, 5Aix-Marseille University, Marseille, France

PR4

5:45 PM - 6:00 PM

A STUDY ON FACTORS INFLUENCING DRUG PRICES AMONG NATIONAL PUBLIC HOSPITALS IN THE PHILIPPINES

Apostol GL
Epimetrics, Inc., Quezon City, Philippines
6:00 PM - 7:30 PM
EXHIBITORS' RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I
6:30 PM - 7:30 PM
RESEARCH POSTER AUTHOR DISCUSSION HOUR - SESSION I
7:30 PM - 9:00 PM
ASIA CONSORTIUM RECEPTION
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.